<DOC>
	<DOC>NCT00234533</DOC>
	<brief_summary>The main purpose of this study is to establish an optimal monitoring regimen in NutropinAq treated children, using newly developed capillary blood spot IGF-1 measurement technology.</brief_summary>
	<brief_title>Study to Define Optimal IGF-1 Monitoring in Children Treated With NutropinAq</brief_title>
	<detailed_description />
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Turner Syndrome</mesh_term>
	<mesh_term>Gonadal Dysgenesis</mesh_term>
	<mesh_term>Primary Ovarian Insufficiency</mesh_term>
	<mesh_term>Renal Insufficiency, Chronic</mesh_term>
	<mesh_term>Dwarfism</mesh_term>
	<mesh_term>Pituitary Diseases</mesh_term>
	<criteria>Children under 18 with growth failure associated with inadequate growth hormone secretion, or Turner syndrome or chronic renal insufficiency. Children with closed epiphyses Children with active neoplasm Children with acute critical illness</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>May 2009</verification_date>
	<keyword>growth</keyword>
	<keyword>child development</keyword>
	<keyword>growth hormone</keyword>
	<keyword>inadequate growth hormone secretion</keyword>
	<keyword>growth failure</keyword>
</DOC>